Gilead Sciences (GILD) ended the recent trading session at $91.86, demonstrating a -0.57% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for ...

California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human ...

Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the ...

Many HIV/AIDS researchers are hopeful that the drug, developed by American biopharmaceutical company Gilead Sciences, will powerfully drive down global infection rates when used as pre-exposure ...

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from ...

Cancer drug company Gritstone Bio Inc. will sell off its pieces to three bidders through U.S. Bankruptcy Court, aiming for a ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.